溴隐亭作为一种潜在的降糖药物用于治疗伴有2型糖尿病的泌乳素瘤。

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.

作者信息

Oshige Tamami, Nakamura Yui, Sasaki Yuko, Kawano Seiko, Ohki Tsuyoshi, Tsuruta Munehisa, Tokubuchi Ichiro, Nakayama Hitomi, Yamada Kentaro, Ashida Kenji, Tajiri Yuji, Nomura Masatoshi

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan.

Asakura Medical Association Hospital, Japan.

出版信息

Intern Med. 2019 Nov 1;58(21):3125-3128. doi: 10.2169/internalmedicine.2755-19. Epub 2019 Jun 27.

DOI:10.2169/internalmedicine.2755-19

PMID:31243214

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6875449/

Abstract

A 22-year-old Japanese woman consulted an endocrinologist due to persistent galactorrhea for the past 10 months. She had hyperprolacinemia and had previously been diagnosed with type 2 diabetes mellitus based on her glycohemoglobin level of 11.6%. After two months, she was admitted to our hospital and finally diagnosed with prolactinoma. For the treatment of prolactinoma, bromocriptine 2.5 mg/day was started. After seven days, her post-prandial blood glucose levels, homeostasis model assessment of insulin resistance and plasma C-peptide levels were significantly improved. These results indicate that traditional bromocriptine can be an effective therapeutic alternative in patients with prolactinoma complicated with type 2 diabetes.

摘要

一名22岁的日本女性因持续泌乳10个月而咨询了内分泌科医生。她患有高泌乳素血症，此前根据糖化血红蛋白水平为11.6%被诊断为2型糖尿病。两个月后，她入住我院，最终被诊断为泌乳素瘤。为治疗泌乳素瘤，开始使用溴隐亭，剂量为2.5毫克/天。七天后，她的餐后血糖水平、胰岛素抵抗的稳态模型评估以及血浆C肽水平均显著改善。这些结果表明，传统的溴隐亭对于合并2型糖尿病的泌乳素瘤患者可能是一种有效的治疗选择。